Wounds and Injuries

All Conditions

Neoplasms

Symptoms and General Pathology

Rupture

Cysts

Pathological Conditions, Anatomical

Central Nervous System Depressants

All Drugs and Chemicals

Anti-Inflammatory Agents

Respiratory System Agents

Bupivacaine

Betamethasone

Betamethasone Valerate

Betamethasone-17,21-dipropionate

Betamethasone benzoate

Betamethasone sodium phosphate

Betamethasone acetate phosphate

Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.

Percutaneous zygapophyseal cyst rupture

Øivind Gjertsen, Md, Msc

Lumbar zygapophyseal joint cysts can cause lower extremity radiculopathy. These cysts can be cured by a minimally invasive technique: percutaneous cyst distention and rupture

Lumbar zygapophyseal joint cysts can cause lower extremity radiculopathy. These cysts can be cured by a minimally invasive technique: percutaneous cyst distention and rupture.

30 patient with lower extremity radiculopathy caused by lumbar zygapophyseal joint cysts will be included in the study.

Percutaneous Rupture of Zygapophyseal Joint Cysts

Ullevaal University Hospital

Head of Research, Division for Radiology and Nuclear Medicine

Musculoskeletal Diseases

Neoplasm Metastasis

Fractures, Bone

Bone Neoplasms

Patients treated by percutaneous CT-guided procedures in the bone with the EPIONE® device

The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures (thermal ablation, bone consolidation, biopsy procedures).

CT-guided bone percutaneous procedure

Laetitia P Messner

Silène P Launay

Thierry DE BAERE

Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for bone percutaneous procedures.

The Epione device is an image-guided robotized device that assists the physician during CT-guided procedures.

EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy

Evaluation of the EPIONE Robotic System for Image-guided Percutaneous Bone Procedures A Prospective Study on Feasibility, Safety and Accuracy

Assessment of the feasibility of the EPIONE robotic system assistance for bone percutaneous procedures based on a definition of conversion to manual technique

Quantum Surgical

Respiratory Tract (Lung and Bronchial) Diseases

Infections

Lung Neoplasms

Abscess

Patients treated by percutaneous CT-guided procedures in the lung with the EPIONE® device

The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.

EPIONE device

THIERRY DE BAERE, MD

Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for percutaneous procedures in the lung.

The objectives are:

* to evaluate the technical success of the device
* to evaluate performance parameters (accuracy measures, adjustements, post-intervention ablation success, local tumor recurrence)
* to evaluate the safety of the device

  25 subjectsare planned and will undergo an intervention, during which the clinician will use the EPIONE device

EPIONE Guided Lung Evaluation

Prospective Clinical Investigation on the Evaluation of Performance and Safety of the EPIONE Assisted CT-guided Percutaneous Procedures in the Lungs

Number of targets reached ; the target is considered reached when the needle is positioned accurately enough to allow the planned procedure to be performed.

accuracy of the needle placement: deviation between the planned and actual needle position once inserted.

Detail of the number/nature of adjustments performed after the initial insertion of the needle.

Minimal Ablation Margin(s) measure(s) (mm) (if aplicable)

Evaluation of the local tumor progression following the ablation (if applicable)

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

patients receive questionnaires regarding socioeconomic aspects before, during and after therapy

questionnaires

Annedore Strnad, MD, MHBA

Rainer Fietkau, MD

This trial is an interrogation of patients with prostate cancer to evaluate socioeconomic effects of radiotherapy. Patients with percutaneous or interstitial or combined percutaneous and interstitial radiotherapy are included. Beside medical effects and adverse events, it's prospectively needed to extensively inform patients about socioeconomic aspects associated with radiotherapy. The interrogation comprises to collect possible costs and expenditures during and after therapy. Aspects especially concerning post therapy period include additional consultations, individual applied alternative medical care, need for additional medical aids (salves, medicine, bandages) and changes in professional and social situation. It's figured out in what extend costs are absorbed by health insurance coverage. In Germany there is no appropriate trial with respective patient population and respective therapy. Primary endpoint is the evaluation of therapy concerning and follow-up costs as well as changes in social and professional situation. Secondary endpoints are quality of life, adverse events of therapy and the correlation of quality of life, adverse events and economic aspects for the patient and the health insurance coverage.

Socioeconomic Aspects Before and After Radiation Therapy in Patient With Prostate Cancer

Evaluation of Socioeconomic Aspects Before and After Primary Radiation Therapy (Percutaneous or Interstitial or Combined Percutaneous and Interstitial) in Patients With Prostate Cancer

by questionnaires concerning social aspects and quality of life to evaluate connections between these parameters

University of Erlangen-Nürnberg Medical School

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Kidney Neoplasms

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Urologic Neoplasms

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.

Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.

Irreversible Electroporation (IRE)

Antje Wiede, Dr.

Johann J. Wendler, Dr. med.

Sandra Böttcher, Dr.

Albert Roessner, Prof.

Jens Ricke, Prof.

Frank Fischbach, Prof.

Maciej Pech, Prof.

Julian Jürgens

Markus Porsch, Dr.

Andreas Janitzky, Dr.

Daniel Baumunk, Dr.

Daniel Schindele, Dr.

Simon Blaschke

Jens Köllermann, PD Dr. med.

Jens Köllermann, PD Dr. med

Uwe- B. Liehr, Dr. med.

Martin Schostak, Prof. Dr.

The aim of the study is the evaluation of the ablation efficiency of the percutaneous irreversible electroporation (IRE) as primary ablation therapy of locally confined renal cell carcinoma (≤4cm, see inclusion and exclusion criteria).

The ablation success will be proofed by magnet resonance imaging (MRI) and histologically after partial kidney resection or nephrectomy 4 weeks after IRE. Hypotheses: Kidney tumors ≤4cm can be ablated completely by percutaneous IRE. Surrounded structures and renal tissue can be preserved.

Health Condition or Problem studied:

1. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD10): C64 - Malignant neoplasm of kidney, except renal pelvis
2. ICD10: D41.0 - Neoplasm of uncertain or unknown behaviour: Kidney

Interventions/Observational Groups Arm 1:

1. Initial diagnostical examination of the renal mass.
2. If any extended diagnostical examination for treatment planning.
3. Day -29 to -1: Recruitment.
4. Day -1: MRI of the kidney, Karnofsky, physical examination, blood chemistry, urosonography, if any renal scintigraphy, life quality assessment.
5. Day 0: Percutaneous diagnostical biopsy with histopathological investigation and therapeutically, CT- and/or ultrasound-guided, ECG-synchronized irreversible electroporation (IRE) of the kidney tumor in endotracheal anaesthesia und muscle relaxation. Use of 1-6 IRE probes with 90-100 pulses of 1500-3000 volts und 20-50 amperes each.
6. Day 1-7: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical examination, blood chemistry, urosonography, life quality assessment.
7. Day 27: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical examination, blood chemistry, urosonography, if any renal scintigraphy, life quality assessment.
8. Day 28: Open surgery partial kidney resection or tumor nephrectomy of the IRE treated kidney resp. kidney tumor region with histopathological investigation.
9. Day 29-37: Postoperative follow-up: physical examination, blood chemistry, urosonography, life quality assessment.
10. Day 112: Study-Follow-up: MRI of the kidneys, Karnofsky, physical examination, blood chemistry, urosonography, if any renal scintigraphy, life quality assessment. Termination of the study.
11. Study closed, Individual follow-up due to the European Association of Urology guideline.

Recruitment:

* (Anticipated or Actual) Date of First Enrollment: 2013/10/14
* Planned/Actual: Opened
* Target Sample Size: 20
* Monocentric/Multicentric trial: Monocentric trial
* National/International: National

IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.

Prospective, Monocentric, Clinical Phase-I/II Study of the Effectiveness of the Percutaneous Irreversible Electroporation (IRE) of Locally Confined Kidney Tumors (Renal Cell Carcinomas).

onco-therapeutic effectiveness, measured against persistent active tumor / cancer cells by histopathological and magnet resonance imaging analysis

* adverse effects
* Assessment of the procedural compliance
* Assessment of the Quality of Life (QoL)

University of Magdeburg

Dr. med.

Blood and Lymph Conditions

Lymphocele

Lymphatic Diseases

Patients with symptomatic lymphocele who are managed with percutaneous drainage and sclerotherapy.

Patients with symptomatic lymphocele who are managed with percutaneous drainage alone.

Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.

Drainage and sclerotherapy.

Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).

Drainage alone.

Maciej Stukan

Maciej Stukan, MD

Symptomatic lymphocele (LC) can be a complication after pelvic and para-aortic lymphadenectomy performed for treatment or staging purposes in the management of some cancers. Management procedures are: single or repeated puncture, prolonged drainage with drains or catheters, mostly followed by sclerotherapy, or surgery. A decision, which management option is most optimal, should be guided by two principles: first to control patient's symptoms, second to apply the least invasive but effective way to treat LC, taking into account that the patient has undergone major surgery recently, and often needs adjuvant treatment at the moment when symptomatic LC is diagnosed.

The aim of this study is to validate feasibility, safety and efficacy of a minimally invasive management of a symptomatic LC - drainage with the usage of vascular catheter followed by sclerotherapy, as well as to evaluate patient's experience on the treatment.

Patients with symptomatic LC are evaluated with ultrasound. Data about diameters, estimated volume of LC and other organs failure if appear is recorded. Management options are discussed with patient, and if the method with catheter insertion and drainage is chosen than the patient is eligible for the study. After vascular catheter insertion into LC and fluid evacuation, patient is followed with active drainage. Patients with drainage only are observed for a short period of time (up to 7 days), and if not efficient a sclerotherapy is considered. In case a patient does not agree to sclerotherapy, or there are contraindications, or it is doctor's decision that drainage alone is sufficient, than the prolonged drainage without sclerotherapy is the only procedure. The choice about the regimen used for sclerotherapy, it's volume, time intervals between repeated infusion depend on institution practice.

Data concerning feasibility, safety and efficacy are noted in designated templates. Patients' experience on the treatment is evaluated with formal questionnaire FACIT-TS-G.

The study is observational. Primary outcome measure is to establish efficacy of the method. Secondary outcome measures are safety and patient's experience on the treatment.

Investigators hope to establish step-by-step guidelines for optimal, minimally invasive management of symptomatic lymphocele.

Management of Symptomatic Post-operative Lymphocele

Management of Symptomatic Post-operative Lymphocele With an Patient-controlled, Vascular Catheter: A Validation Study

measured with a questionnaire FACIT-TS-G (Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General) available from http://www.facit.org/facitorg/questionnaires. Permission to use obtained.

Successful lymphocele treatment means complete resolution of lymphocele after minimally invasive procedures - percutaneous drainage with a vascular catheter followed by sclerotherapy or drainage alone. Opposite - non successful treatment defined when the patient is refered for a surgical management.

Maciej Stukan, MD, PhD

Hematinics

Liver Extracts

Patients treated by percutaneous CT-guided procedures in the abdomen with the EPIONE® device

EPIONE® CT-Guided Percutaneous procedures

Post-Market Clinical Follow-up study in order to consolidate performance and safety data of the EPIONE® device when used for percutaneous procedures in the abdomen

The objective of this PMCF study is to compile data on the routine use of the EPIONE® device in subjects undergoing CT-guided percutaneous procedures in the abdomen.

The objectives are:

1. to evaluate the technical success of the device
2. to evaluate performance parameters (accuracy measures, adjustements, post-intervention ablation success, local tumor recurrence, operator satisfaction) and the safety of the device

55 patients are planned in this post-market study.

Epione® Post-Market Clinical Follow-up Study

Post-Market Clinical Follow-Up Study of a Robotic Device for Image Guided Percutaneous Needle Placement in the Abdomen

Number of targets reached ; the target is considered to have been reached when the needle is positioned accurately enough to allow the planned procedure to be performed.

accuracy of the needle placement: deviation between the planned and actual needle position once inserted

Detail of the number/nature of adjustments performed after the initial insertion of the needle

Minimal Ablation Margin(s) measure(s) if applicable (mm)

5-point Likert scale: very Dissatisfied/dissatisfied/neutral/satisfied/highly satisfied

Neoplastic Processes

Tin Fluorides

A single arm with patients with advanced cancer who have all of the following:

1. refractory pain and/or gait disturbance caused by pelvic bone metastasis, did not respond to conservative treatment.
2. osteolytic lesion (in predominance) suitable for the pain.
3. limited life expectancy (less than 3 years) or stopping medical treatment.

Exclusion criteria:

There are no absolute contraindications for the procedure; however, the relative contraindications are:

1. patients in poor condition with an expected survival period of less than 3 months.
2. patients with stable course, with long life expectancy (more than 3 years) or those considered candidates for major pelvic surgery including tumor removal and hip arthroplasty.
3. presence of bone destruction with soft tissue mass contaminating important organs, nerves and blood vessels (improvement is not expected).
4. Patients refusing to give a written consent to the study protocol.

Percutaneous image guided cementoplasty will be performed as follows:

Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely

Percutaneous cementoplasty

This study aimed to summarize the immediate operative and short-term efficacy and safety outcomes of percutaneous cementoplasty for pelvic metastases

Bone metastasis (BM) is the major cause of morbidity in patients with cancer. After lungs and liver, bone is the third most common site of metastatic disease. Prostate and breast cancers are responsible for the majority of bone metastases (up to 70%), followed by thyroid, lung, urinary bladder, and renal cancers, and finally melanoma. The incidence of bone metastasis is approximately 100,000 new cases per year in the united states and is increasing. Bone metastasis could result in skeletal-related events, including pain, pathological fracture, hypercalcemia, and nerve and visceral compression, which seriously affect the quality of life (QoL) of cancer patients. Bone metastases can be classified as osteolytic (osteoclast-mediated bone resorption), osteoblastic (osteoblast-mediated bone deposition), or mixed.

Fifty percent of the pain symptoms experienced by patients with cancer originate from BM. Tumor extension to neural structures, can cause a pain that may be radicular (exacerbated by percussion or palpation) and/or mechanical (exacerbated by movement). In advanced cases, pain can become intolerable and refractory to conventional therapies, resulting in walking disability, psychological and functional impact, and significant worsening of the QoL.

The effectiveness of surgery for bone metastasis in advanced cancer patients is limited to improvement of patients' quality of life. In most of these patients, complete resection or extended curettage of the bone metastasis with major reconstruction is often not feasible due to their poor general condition and accompanying other metastases. For some types of these bone metastases, surgical resection can lead to the stripping of the surrounding soft tissue and muscle attachment and addressing bone defects, causing more intraoperative bleeding, prolonged healing time, and increase the risk of wound complications, which in turn result in a longer recovery time for patients who usually have a limited life expectancy. Therefore, less invasive procedures, including percutaneous ablation (microwave ablation, radiofrequency ablation, cryoablation, and high-energy ultrasound) and/or bone cement \[polymethylmethacrylate (PMMA)\] injection, have become possible options. This is especially true for pelvic metastatic lesions because the surgery is particularly burdensome.

In addition, life expectancy of patients with metastatic bone disease is the most important factor in the decision making for surgical and/or medical treatment. A short life expectancy is in favor of the use of less invasive procedures, that have lower complication rates and shorter rehabilitation times. In these situations, interventional radiology procedures play an important either primary or complementary role in the management of bone metastases, especially in terms of palliation of pain, improvement of ambulation problems and treatment of fractures. This is because short life expectancies, more often, require palliative rather than curative regimens and make rapid pain relief to become a priority.

Aim of the study This study aimed to summarize the immediate operative and short-term efficacy and safety outcomes of percutaneous cementoplasty for pelvic metastases.

Materials and methods

Target Patients:

The study will include 20 patients with advanced cancer fulfilling the inclusion criteria and giving an informed consent to the study protocol (a single arm).

The following data will be collected from all patients:

1. Age at the time of the procedure
2. Gender
3. Primary cancer
4. Presence of lung metastasis
5. Presence of peritoneal metastasis
6. From the total bone scan:

   1. Unilateral or bilateral pelvic bone metastasis
   2. Solitary or oligometastasis (less than three sites) or multimetastasis ( 3 sites or more).
   3. Presence or absence of spine metastasis
   4. Presence or absence of lower limb metastasis
7. Previous surgery for cancer (site of the operation; pelviabdominal, lower limbs, spine, chest, brain)
8. Chemotherapy (preoperative, postoperative or both)
9. Radiotherapy (preoperative, postoperative or both)

Procedure:

The procedure will be performed under either spinal or general anesthesia. The patient will be placed in the lateral decubitus position with the surgical side up. The needle entry point will be adjusted with a fluoroscopic guide near the point 10 cm posterior to the anterior superior iliac spine. The skin and bone will be punctured by a 11-gauge needle. At least 2 or 3 different routes to the lesion will be established, and one needle will remain empty to allow decompression if possible.

The detailed procedure is described in the intervention section below. During the injection of PMMA, the anesthesiologist carefully will monitor the change in blood pressure and pulse rate, given the known toxicity of bone cement. The injected dose will vary according to the number of metastatic sites injected and their sizes.

All patients who has no contraindication to anticoagulation will be given (enoxaparin 40-60 mg per day) from 1 day before the procedure until ambulation was resumed for deep vein thrombosis prophylaxis.

The following procedural data will be collected:

1. Total cement amount
2. Injection needle number
3. Injection site number
4. Injected sites (Iliac bone or crest, acetabulum, ischium, pubic)
5. Duration of the procedure (in minutes)
6. Type of anesthesia used
7. If any other operation is performed concomitantly (nominate).

Outcome measures:

Primary outcome: is pain reduction:

Secondary outcomes: are

I- Gait function:

1. Gait status will be recorded pre and post operative
2. Gate function change II- Complications of the procedure (if more than one complication occurred in the same patient, all complications will be recorded)

A. Local:

1- Extraosseous bone leakage 2- Pathological fracture of the pelvic bones B. Systemic

1. Mortality
2. Pulmonary embolism
3. Bone cement implantation syndrome (BCIS):

Follow-up outcomes: at one month and 3 months

1. Mortality
2. Pain relapse (NRS score)
3. Gait relapse
4. Pathological fracture in the pelvic bones at the treated sites (by bone window CT).

Imaging Guided Cementoplasty for Pelvic Bone Metastasis

Immediate and Short-term Outcomes of Imaging Guided Percutaneous Cementoplasty for Pelvic Bone Metastases

To evaluate pain, the numerical pain score (NRS) will be used. The NRS is an 11-point numerical scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain (Figure 3) and pain is classified as mild pain if 1-4 points (tolerable), moderate if 5-6 points and severe if 7-10 points. NRS has been shown to be particularly reliable especially among patients with low health literacy. The NRS is also simple to score, and can be administered both orally and in written form.

Gait status will be recorded pre and post operative: with the following order from better to worse i. Normal ii. Limping iii. Independent with crutch or cane iv. Wheelchair v. Bed-ridden vi. Dead

It is a safety local outcome that reports extraosseous cement leakage (intra-articular "nominate joint", elsewhere)

A safety local outcome that is reported by history and confirmed by CT that could be impending or displaced

procedure related mortality is considered within 2 weeks of the procedure

(Pulmonary embolism caused by thrombus, fat, tumor emboli, or bone cement will be diagnosed by pulmonary CT with contrast if clinically suspected). For pulmonary embolism, clinical or radiological factors that might be related to its occurrence were collected, including primary cancer type, presence of lung metastasis, injected cement amount and number, local cement leakage during the procedure, pathologic fracture at the site for procedure, and injected route number.

1- defined as hypoxia, hypertension or both, and/or unexpected loss of consciousness occurring around the time of cementation. BCIS will be classified according to severity of symptoms:

1. grade 1 was moderate hypoxia (SpO2 \< 94%) or hypotension (fall in SBP \> 20%)
2. grade 2 was severe hypoxia (sPO2\<88%) or hypotension (fall in SBP\>40%) or unexpected loss of consciousness
3. grade 3 was cardiovascular collapse requiring cardiopulmonary resuscitation (CPR).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Percutaneous Rupture of Zygapophyseal Joint Cysts	NCT00837070	Zygapophyseal S...	Percutaneous zy...	20 Years -	Oslo University Hospital
EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy	NCT06376682	Bone Metastases Fractures, Bone Bone Tumor	CT-guided bone ...	18 Years -	Quantum Surgical
EPIONE Guided Lung Evaluation	NCT05651867	Lung Cancer	EPIONE device	18 Years -	Quantum Surgical
EPIONE Guided Lung Evaluation	NCT05651867	Lung Cancer	EPIONE device	18 Years -	Quantum Surgical
EPIONE Guided Lung Evaluation	NCT05651867	Lung Cancer	EPIONE device	18 Years -	Quantum Surgical
Socioeconomic Aspects Before and After Radiation Therapy in Patient With Prostate Cancer	NCT01849471	Prostate Cancer	questionnaires	18 Years -	University of Erlangen-Nürnberg Medical School
IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.	NCT01967407	Kidney Tumor Renal Cell Canc...	Irreversible El...	18 Years -	University of Magdeburg
Management of Symptomatic Post-operative Lymphocele	NCT02800980	Lymphocele	Drainage and sc... Drainage alone.	18 Years -	Gdynia Oncology Center
Epione® Post-Market Clinical Follow-up Study	NCT05529979	Cancer Abdomen	EPIONE® CT-Guid...	18 Years -	Quantum Surgical
Management of Symptomatic Post-operative Lymphocele	NCT02800980	Lymphocele	Drainage and sc... Drainage alone.	18 Years -	Gdynia Oncology Center
Imaging Guided Cementoplasty for Pelvic Bone Metastasis	NCT06231628	Imaging Guided Percutaneous Ce... Pelvic Bone Met...	Percutaneous ce...	-	Assiut University
Imaging Guided Cementoplasty for Pelvic Bone Metastasis	NCT06231628	Imaging Guided Percutaneous Ce... Pelvic Bone Met...	Percutaneous ce...	-	Assiut University

Spots Global Cancer Trial Database for percutaneous

Every month we try and update this database with for percutaneous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.